Researchers have developed intricately patterned 3D tissue constructs with multiple types of cells and tiny blood vessels. The work could provide tissues that are realistic enough to screen drugs for safety and effectiveness. Ultimately it offers the potential for reconstructive surgery.
Varicose Vein treatments typify the adoption of new technologies, factors such as economics, reimbursement and clinical resistance all playing their part in ensuring that the old ways, while in decline, will endure for a while yet.
A range of silicone breast implants with integrated RFID technology has been CE Marked. This means key data about the implants can be easily retrieved with the sweep of a scanner, rather than resorting to hospital records in the event of a recall or other clinical need.
This is the first time we’ve ventured out into the world of aesthetic treatments, with the news that the FDA has given its blessing to a device that exploits the benefits of different forms of light to effect hair removal.
Global Pharma company Shire plc, is to sell what it calls its “Dermagraft assets” to Organogenesis Inc. for what could add up to $300 million, but for now looks like a $650 million loss.
A division of GC Aesthetics, Nagor is the only breast implant manufacturer based in Britain. And in a piece of elegant commercial symmetry it has just announced that it is now launching its range in France, no doubt hoping its quality message and reputation will score heavily in the aftermath of a certain other silicone breast manufacturer.
Surgical Adhesive manufacturer Cohera Medical, Inc.® has submitted its fourth and final FDA PMA module that would ultimately see TissuGlu® indicated for reducing drainage following abdominoplasty procedures in the US.
It seems San Francisco’s Invuity, Inc., has hit on a rich vein of unmet need as its clever illuminated retractor systems featured heavily in the last two weeks at both an anterior hip arthroplasty course and an innovation technology showcase hosted by one of the big healthcare supply chain companies.
Aesthetic medical device company Syneron Medical Ltd., has announced FDA clearance and CE mark approval for VelaShape® III, the Company’s new non-invasive body shaping platform. This new platform is said to be effective for temporary reduction in circumference of the abdomen and is also used in a wide range of other body shaping applications such as cellulite treatments.
Cardium Therapeutics has reported on a research collaboration with researchers at Boston Children’s Hospital, to assess the medical utility of Excellagen® as a delivery scaffold to seed autologous mesenchymal fetal stem cells for ex-vivo engineering of tissue grafts for transplantation into infants to repair prenatally diagnosed birth defects.
Aesthetic Breast expert Mentor Worldwide LLC, has announced the U.S. FDA approval of its MENTOR® MemoryShape™ Breast Implants, providing new options for women looking for a more natural shape and youthful feel from breast enhancement or reconstruction surgery.
Implant company RTI Biologics Inc. has launched its Fortiva™ porcine dermis implant at the Abdominal Wall Reconstruction (AWR) Conference in … continue reading “RTI Biologics® Sees Launch And First Use Of Fortiva™ Porcine Dermis In Hernia”
When Sweden’s device authority called for all PIPs to be removed last week their evidence was seized upon by UK … continue reading “UK Plastic Surgeons Jump On Swedish PIP Results”
TEI Biosciences, Inc. has gained FDA Investigational Device Exemption (IDE) approval to initiate a human clinical trial to gain specific … continue reading “Trial Will Test SurgiMend® PRS Breast Cancer Reconstruction Claims”
According to a release from the UK’s MHRA, its Swedish equivalent has adopted the position that PI implants should be removed as a precautionary measure. The MHRA has issued its own statement reasserting its position that this is not necessary in all cases.
Somehow the idea that using an illicit material in a bodily implant is now OK, regardless of whether it’s approved. So claim the defendants in the PIP case which has seen its closing remarks today. This cavalier approach is what got PIP into hot water, but they seem to be in a state of denial that they’ve done much wrong at all.